Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Patients must not have received enzyme-inducing anticonvulsants for at least  days prior to enrollment
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Patients must not have received enzyme inducing anticonvulsants for at least  days prior to enrollment
Patients with seizure disorder may be enrolled if on non-enzyme inducing anti-convulsants and well controlled
Patients must not have received enzyme-inducing anticonvulsants for at least  days prior to enrollment
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled; however, drugs that induce CYPA/ (carbamazepine, oxcarbazepine, phenytoin, primidone, phenobarbital) should be avoided
Central nervous system function defined as:\r\n* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled\r\n* Patients must not be in status epilepticus, a coma or on assisted ventilation at the time of study enrollment
Patients with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures may be enrolled
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Concomitant use of any enzyme inducing anticonvulsants is not allowed
Subjects who are currently receiving enzyme inducing anticonvulsants are not eligible
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Patients must not currently be receiving enzyme inducing anticonvulsants
Patients receiving concomitant medication that may interfere with study outcome; for example, patients cannot be on enzyme inducing anticonvulsants like phenytoin
Patients receiving treatment with any enzyme-inducing anticonvulsant that cannot be discontinued at least  week before first dose of INC, and for the duration of the study; patients on non-enzyme-inducing anticonvulsants are eligible
Patients with seizure disorder may be enrolled if receiving non-enzyme inducing anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled.
Patients with known seizure disorder must have seizures adequately controlled with non- enzyme inducing antiepileptic medications
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Adequate central nervous system function defined as:\r\n* Subjects with seizure disorder may be enrolled if on anticonvulsants and seizures are well controlled
Patients with seizure disorder may be enrolled if receiving non-enzyme inducing anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Patients who are currently receiving enzyme inducing anticonvulsants are not eligible
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Anticonvulsants: patients on enzyme inducing anticonvulsants (EIAED) will be excluded; if patients were previously on EIAEDs that have been discontinued, patients must have been off EIAEDs for >=  weeks prior to initiation of dasatinib
Patients with a seizure disorder may be enrolled if well-controlled and on non-enzyme inducing anticonvulsants
Patients with a seizure disorder are study eligible if seizures are controlled on anticonvulsants
Patients with seizure disorder may be enrolled if well controlled; patients receiving enzyme-inducing anticonvulsants are not eligible for this study; patients must be off enzyme inducing anticonvulsant drugs (EIACD) for at least  weeks prior to registration
Patients on enzyme inducing anticonvulsants
Concomitant use of any enzyme inducing anticonvulsants is not allowed
Subjects with seizure disorder may be enrolled if on anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
TUMOR BIOPSY SEQUENCING: Patients with history of central nervous system (CNS) metastases who have received treatment and who either have not had seizures or have been on stable doses of anti-seizure medicine and had no seizures for  weeks will be eligible; enzyme-inducing anticonvulsants are contraindicated
Patients with seizure disorder may be enrolled if on anticonvulsants and if seizures are well controlled
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Central nervous system function defined as:\r\n* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled\r\n* Patients must not be in status, coma or assisted ventilation prior to study enrollment
Brain metastases that are symptomatic or requiring corticosteroids (except inhaled); subjects must also be off of enzyme-inducing anticonvulsants for >  weeks
Central nervous system function defined as\r\n* Patients with a seizure disorder may be enrolled if well-controlled and on non-enzyme inducing anticonvulsants
Patients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, valproic acid, or carbamazepine for at least  days prior to study enrollment; patients receiving non-enzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligible
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and if seizures are well controlled
Patients who are currently receiving enzyme inducing anticonvulsants are not eligible
Patients with known seizure disorder must have seizures adequately controlled with non-enzyme inducing antiepileptic medications
Participants who are currently receiving enzyme-inducing anticonvulsants
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Patients taking enzyme inducing anticonvulsants
Use of enzyme-inducing anticonvulsants (EIACs); a minimum interval of  days between the last dose of EIAC and start of this therapy will be required for research participants who were previously receiving such medications
Central nervous system function defined as:\r\n* Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and if seizures are well controlled\r\n* Nervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version  [v]) resulting from prior therapy must be =< grade 
Patients who are currently receiving enzyme inducing anticonvulsants are not eligible
Subjects with seizure disorder may be enrolled if on anticonvulsants and seizures are well controlled
No enzyme inducing anticonvulsants for >=  weeks prior to randomization
Central Nervous System: Patients without seizure disorder OR patients with well-controlled seizure disorder receiving anticonvulsants may be enrolled on this protocol; anticonvulsants must not be enzyme-inducing (inducers of CYPA, i.e., no barbiturates, phenytoin, carbamazepine, etc.)
Patients with seizure disorder may be enrolled if on anticonvulsants and well-controlled; central nervous system (CNS) toxicity < grade 
Patients must not have received enzyme inducing anticonvulsants for at least  days prior to enrollment
Patients with seizure disorders treated with anticonvulsants
Patients with a seizure disorder are eligible if well-controlled on anticonvulsants; if on a non-enzyme inducing anticonvulsant, the irinotecan (irinotecan hydrochloride) dose will be adjusted as outline in treatment plan
Patients with brain metastases are eligible provided they meet all other eligibility criteria and do not require corticosteroids or enzyme-inducing anticonvulsants and provided it is felt clinically that they will not require radiotherapy in the three () weeks subsequent to their participation in the study